Prevalence of Mutations in the pfcoronin Gene and Association with Ex Vivo Susceptibility to Common Quinoline Drugs against Plasmodium falciparum

Background: Artemisinin-based combination therapy (ACT) was recommended to treat uncomplicated falciparum malaria. Unlike the situation in Asia where resistance to ACT has been reported, artemisinin resistance has not yet emerged in Africa. However, some rare failures with ACT or patients continuing to be parasitaemic on day 3 after ACT treatment have been reported in Africa or in travellers returning from Africa. Three mutations (G50E, R100K, and E107V) in the pfcoronin gene could be responsible for artemisinin resistance in Africa. Methods: The aims of this study were first to determine the prevalence of mutations in the pfcoronin gene in African P. falciparum isolates by Sanger sequencing, by targeting the 874 samples collected from patients hospitalised in France after returning from endemic areas in Africa between 2018 and 2019, and secondly to evaluate their association with in vitro reduced susceptibility to standard quinoline antimalarial drugs, including chloroquine, quinine, mefloquine, desethylamodiaquine, lumefantrine, piperaquine, and pyronaridine. Results: The three mutations in the pfcoronin gene (50E, 100K, and 107V) were not detected in the 874 P. falciparum isolates. Current data show that another polymorphism (P76S) is present in many countries of West Africa (mean prevalence of 20.7%) and Central Africa (11.9%) and, rarely, in East Africa (4.2%). This mutation does not appear to be predictive of in vitro reduced susceptibility to quinolines, including artemisinin derivative partners in ACT such as amodiaquine, lumefantrine, piperaquine, pyronaridine, and mefloquine. Another mutation (V62M) was identified at low prevalence (overall prevalence of 1%). Conclusions: The 76S mutation is present in many African countries with a prevalence above 10%. It is reassuring that this mutation does not confer in vitro resistance to ACT partners.

[1]  E. Schmitt,et al.  High Prevalence of Plasmodium falciparum K13 Mutations in Rwanda Is Associated With Slow Parasite Clearance After Treatment With Artemether-Lumefantrine , 2021, The Journal of infectious diseases.

[2]  L. Mutesa,et al.  Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. , 2021, The Lancet. Infectious diseases.

[3]  B. Pradines,et al.  Absence of Association between Methylene Blue Reduced Susceptibility and Polymorphisms in 12 Genes Involved in Antimalarial Drug Resistance in African Plasmodium falciparum , 2021, Pharmaceuticals.

[4]  F. Mockenhaupt,et al.  Increase in Kelch 13 Polymorphisms in Plasmodium falciparum, Southern Rwanda , 2021, Emerging infectious diseases.

[5]  D. Hartl,et al.  Genetic background and PfKelch13 affect artemisinin susceptibility of PfCoronin mutants in Plasmodium falciparum , 2020, PLoS genetics.

[6]  B. Pradines,et al.  Absence of association between polymorphisms in the pfcoronin and pfk13 genes and the presence of Plasmodium falciparum parasites after treatment with artemisinin derivatives in Senegal. , 2020, International journal of antimicrobial agents.

[7]  D. Fidock,et al.  Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda , 2020, Nature Medicine.

[8]  J. Gomis,et al.  Efficacy and safety of artemisinin-based combination therapy and the implications of Pfkelch13 and Pfcoronin molecular markers in treatment failure in Senegal , 2020, Scientific Reports.

[9]  U. Morris,et al.  Surveillance of genetic markers associated with Plasmodium falciparum resistance to artemisinin-based combination therapy in Pakistan, 2018–2019 , 2020, Malaria Journal.

[10]  B. Pradines,et al.  Changes in malaria epidemiology in France and worldwide, 2000-2015. , 2020, Medecine et maladies infectieuses.

[11]  B. Pradines,et al.  Are k13 and plasmepsin II genes, involved in Plasmodium falciparum resistance to artemisinin derivatives and piperaquine in Southeast Asia, reliable to monitor resistance surveillance in Africa? , 2019, Malaria Journal.

[12]  P. Kremsner,et al.  An alternative dogma on reduced artemisinin susceptibility: A new shadow from east to west , 2019, Proceedings of the National Academy of Sciences.

[13]  R. Piarroux,et al.  Epidemiologic Trends in Malaria Incidence Among Travelers Returning to Metropolitan France, 1996-2016 , 2019, JAMA network open.

[14]  L. Ayong,et al.  Current Situation of Malaria in Africa. , 2019, Methods in molecular biology.

[15]  D. Hartl,et al.  Mutations in Plasmodium falciparum actin-binding protein coronin confer reduced artemisinin susceptibility , 2018, Proceedings of the National Academy of Sciences.

[16]  V. Vullo,et al.  Dihydroartemisinin–piperaquine treatment failure in uncomplicated Plasmodium falciparum malaria case imported from Ethiopia , 2018, Infection.

[17]  P. Bastien,et al.  The D113N mutation in the RING E3 ubiquitin protein ligase gene is not associated with ex vivo susceptibility to common anti-malarial drugs in African Plasmodium falciparum isolates , 2018, Malaria Journal.

[18]  R. Piarroux,et al.  Plasmodium falciparum Recrudescence Two Years after Treatment of an Uncomplicated Infection without Return to an Area Where Malaria Is Endemic , 2017, Antimicrobial Agents and Chemotherapy.

[19]  B. Pradines,et al.  Absence of association between polymorphisms in the K13 gene and the presence of Plasmodium falciparum parasites at day 3 after treatment with artemisinin derivatives in Senegal. , 2017, International journal of antimicrobial agents.

[20]  Mehul Dhorda,et al.  The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study , 2017, The Lancet. Infectious diseases.

[21]  P. Ringwald,et al.  Efficacy of artemether–lumefantrine, artesunate–amodiaquine, and dihydroartemisinin–piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in Angola, 2015 , 2017, Malaria Journal.

[22]  Dhruviben S. Patel,et al.  Efficacy of artemether–lumefantrine, artesunate–amodiaquine, and dihydroartemisinin–piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in Angola, 2015 , 2017, Malaria Journal.

[23]  M. Berriman,et al.  pfk13-Independent Treatment Failure in Four Imported Cases of Plasmodium falciparum Malaria Treated with Artemether-Lumefantrine in the United Kingdom , 2017, Antimicrobial Agents and Chemotherapy.

[24]  F. Gobbi,et al.  Failure of dihydroartemisinin-piperaquine treatment of uncomplicated Plasmodium falciparum malaria in a traveller coming from Ethiopia , 2016, Malaria Journal.

[25]  J. Ndiaye,et al.  West Africa International Centers of Excellence for Malaria Research: Drug Resistance Patterns to Artemether-Lumefantrine in Senegal, Mali, and The Gambia. , 2016, The American journal of tropical medicine and hygiene.

[26]  F. Frischknecht,et al.  The Actin Filament-Binding Protein Coronin Regulates Motility in Plasmodium Sporozoites , 2016, PLoS pathogens.

[27]  C. Rogier,et al.  A Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms. , 2016, The New England journal of medicine.

[28]  F. Frischknecht,et al.  Plasmodium falciparum coronin organizes arrays of parallel actin filaments potentially guiding directional motility in invasive malaria parasites , 2015, Malaria Journal.

[29]  S. Briolant,et al.  Multinormal in vitro distribution of Plasmodium falciparum susceptibility to piperaquine and pyronaridine , 2015, Malaria Journal.

[30]  D. Kwiatkowski,et al.  Spread of artemisinin resistance in Plasmodium falciparum malaria. , 2014, The New England journal of medicine.

[31]  B. Genton,et al.  A molecular marker of artemisinin-resistant Plasmodium falciparum malaria , 2013, Nature.

[32]  S. Briolant,et al.  Pfhrp2 and pfhrp3 polymorphisms in Plasmodium falciparum isolates from Dakar, Senegal: impact on rapid malaria diagnostic tests , 2013, Malaria Journal.

[33]  F. Nosten,et al.  Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study , 2012, The Lancet.

[34]  B. Pradines,et al.  Reduced in vitro susceptibility to artemisinin derivatives associated with multi-resistance in a traveller returning from South-East Asia , 2011, Malaria Journal.

[35]  Organización Mundial de la Salud Guidelines for the treatment of malaria , 2010 .

[36]  K. Silamut,et al.  Artemisinin resistance in Plasmodium falciparum malaria. , 2009, The New England journal of medicine.